Showing 1961-1970 of 2659 results for "".
- Bausch + Lomb Receives Health Canada Approval for enVista Envy Full Visual Range IOLhttps://modernod.com/news/bausch-lomb-receives-health-canada-approval-for-envista-envy-full-visual-range-iol/2482293/Health Canada has approved Bausch+Lomb's enVista Envy full visual range IOL. This is the first regulatory approval of the new lens, which is designed to offer a full range of vision with dysphotopsia tolerance on the enVista IOL platform. “enVista Envy
- Researchers Detail How Neurons Build a 3-D Vascular Structure to Keep the Retina Healthyhttps://modernod.com/news/researchers-detail-how-neurons-build-a-3-d-vascular-structure-to-keep-the-retina-healthy/2482292/Scientists have known for years that a lattice of blood vessels nourishes cells in the retina that allow us to see – but it’s been a mystery how the intricate structure is created. Now, researchers at University of California San Francisco have found a new type of neuron that guides i
- New World Medical Receives 510(k) Clearance for KDB GLIDE Expanded Indication for Reduction of IOPhttps://modernod.com/news/new-world-medical-receives-510k-clearance-for-kdb-glide-expanded-indication-for-reduction-of-iop/2482290/New World Medical has announced it has received FDA 510(k) clearance for KDB (Kahook Dual Blade) GLIDE to be used for the reduction of IOP in adult patients with primary open-angle glaucoma (POAG) during cataract surgery or as a standalone procedure. The FDA’s
- Drug Farm Gets Green Light from FDA to Initiate Phase 1b Trial of DF-003 in ROSAH Syndrome Patientshttps://modernod.com/news/drug-farm-gets-green-light-from-fda-to-initiate-phase-1b-trial-of-df-003-in-rosah-syndrome-patients/2482284/The FDA has cleared Drug Farm's investigational new drug (IND) application of DF-003, a first-in-class, oral, potent, highly selective alpha-kinase 1 (ALPK1) inhibitor for clinical evaluation in ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) synd
- Humonix Biosciences Appoints Karen Torrejon, PhD, as New CEOhttps://modernod.com/news/humonix-biosciences-appoints-karen-torrejon-phd-as-new-ceo/2482275/Humonix Biosciences announced the appointment of Karen Torrejon, PhD, as the new Chief Executive Officer. Dr. Torrejon, who originally founded the company in 2014, will now be leading the company as it transitions into a broader, science-driven platform. Humonix’s platform has bee
- Isarna Therapeutics Announces Phase 2 Clinical Data Presentations at Upcoming Ophthalmology Conferenceshttps://modernod.com/news/isarna-therapeutics-announces-phase-2-clinical-data-presentations-at-upcoming-ophthalmology-conferences/2482263/Isarna Therapeutics announced upcoming oral presentations at the OIS Retina Innovation Summit on May 4 and the Association for Research in Vision and Ophthalmology (ARVO) meeting on May 7, both in Seattle. Isarna’s Chief Medical Officer, Prof. Marion R. Munk, will present upd
- Vesigen to Present New Preclinical Data on Ophthalmology Applications of Engineered ARMMs at ARVOhttps://modernod.com/news/vesigen-to-present-new-preclinical-data-on-ophthalmology-applications-of-engineered-armms-at-arvo/2482262/Vesigen Therapeutics announced that the company will be presenting two posters sharing new preclinical data from its engineered ARMMs platform at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Seattle, from May 5-9. Vesigen’s techno
- Johnson & Johnson to Debut EYE-RD Global Registry at ARVOhttps://modernod.com/news/johnson-johnson-to-debut-eye-rd-global-registry-at-arvo/2482261/Johnson & Johnson announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking place in Seattle from May 5–9, 2024. The company's two oral presentations wil
- Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase 1/2 Trial Evaluating Gene Therapy for XLRShttps://modernod.com/news/atsena-therapeutics-announces-positive-clinical-data-from-the-first-cohort-of-phase-12-trial-evaluating-gene-therapy-for-xlrs/2482257/Atsena Therapeutics announced positive preliminary data from the first cohort of the ongoing LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201 utilizes AAV.SPR, the company’s novel sprea
- RetiSpec and Topcon Healthcare Announce Collaboration to Help Bring Eye-Based AI Diagnostic Tool to Markethttps://modernod.com/news/retispec-and-topcon-healthcare-announce-collaboration-to-help-bring-eye-based-ai-diagnostic-tool-to-market/2482256/Topcon Healthcare announced it has invested in RetiSpec and the two companies are collaborating to bring RetiSpec technology to market. The collaboration will bring neurology and eye care closer together. RetiSpec's clinically validated eye diagnostic AI aims to help healthcare